Diamyd Medical AB | Balance Sheet

Fiscal year is September-August. All values SEK Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
65,518.00
35,675.00
29,727.00
31,396.00
85,725.00
Total Accounts Receivable
972.00
781.00
431.00
637.00
840.00
Other Current Assets
603.00
758.00
346.00
918.00
4,509.00
Total Current Assets
67,093.00
37,214.00
30,504.00
32,951.00
91,074.00
Net Property, Plant & Equipment
85.00
-
-
-
-
Total Investments and Advances
639.00
13,705.00
15,035.00
3,827.00
6,679.00
Long-Term Note Receivable
-
-
626.00
626.00
626.00
Intangible Assets
-
106.00
480.00
374.00
268.00
Total Assets
67,817.00
51,025.00
46,645.00
37,778.00
98,647.00
Accounts Payable
1,448.00
1,309.00
935.00
1,221.00
6,368.00
Other Current Liabilities
5,281.00
4,710.00
5,380.00
4,084.00
3,022.00
Total Current Liabilities
6,729.00
6,019.00
6,315.00
5,305.00
9,390.00
Provision for Risks & Charges
-
-
-
3,210.00
2,591.00
Other Liabilities
795.00
841.00
806.00
-
-
Total Liabilities
7,524.00
6,860.00
7,121.00
8,515.00
11,981.00
Common Equity (Total)
60,293.00
44,165.00
39,524.00
29,263.00
86,666.00
Total Shareholders' Equity
60,293.00
44,165.00
39,524.00
29,263.00
86,666.00
Total Equity
60,293.00
44,165.00
39,524.00
29,263.00
86,666.00
Liabilities & Shareholders' Equity
67,817.00
51,025.00
46,645.00
37,778.00
98,647.00

About Diamyd Medical AB

View Profile
Address
Kungsgatan 29
Stockholm AB 111 56
Sweden
Employees -
Website http://www.diamyd.com
Updated 09/14/2018
Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes. It develops vaccine to cure autoimmune diabetes. The firm also involves in investment in medical and stem cell technology.